Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > News > AlphaRx Reports Fiscal 2006 Year End Results

December 21st, 2006

AlphaRx Reports Fiscal 2006 Year End Results

Abstract:
"We are very pleased with the progress we have made in 2006, solidifying our R&D resources in the nanoparticle drug delivery platform, which has resulted in the recent signing of a Feasibility and Option Agreement with a global specialty pharmaceutical company for 3 drug products," stated Michael Lee, President and CEO. "We have also made significant progress this year in executing our strategy of building corporate partnerships and a strong product pipeline for long term growth. In 2007, we intend to focus on advancing our infectious diseases program into human clinical trials, and the pursuit of additional corporate partnerships for product commercialization and development."

Source:
marketwire.com

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025

New imaging approach transforms study of bacterial biofilms August 8th, 2025

Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025

Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025

Announcements

Sensors innovations for smart lithium-based batteries: advancements, opportunities, and potential challenges August 8th, 2025

Deciphering local microstrain-induced optimization of asymmetric Fe single atomic sites for efficient oxygen reduction August 8th, 2025

Japan launches fully domestically produced quantum computer: Expo visitors to experience quantum computing firsthand August 8th, 2025

ICFO researchers overcome long-standing bottleneck in single photon detection with twisted 2D materials August 8th, 2025

Financial Reports

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

180 Degree Capital Corp. Reports +6.7% Growth in Q4 2020, $9.28 Net Asset Value per Share as of December 31, 2020, and Developments from Q1 2021 Including Expected Investment in a Planned SPAC Sponsor February 22nd, 2021

Human Interest/Art

New 2D multifractal tools delve into Pollock's expressionism January 17th, 2025

Drawing data in nanometer scale September 30th, 2022

Scientists prepare for the world’s smallest race: Nanocar Race II March 18th, 2022

Graphene nanotubes revolutionize touch screen use for prosthetic hands August 3rd, 2021

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project